Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers

Authors

  • Fanny Fachrucha Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia https://orcid.org/0000-0001-9450-2180
  • Dianiati Kusumo Sutoyo Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Fariz Nurwidya Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Sita Laksmi Andarini Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia https://orcid.org/0000-0003-0169-1109
  • Agus Dwi Susanto Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Fathiyah Isbaniah Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Diah Handayani Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia https://orcid.org/0000-0002-3647-2670
  • Faisal Yunus Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Dicky Soehardiman Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Jamal Zaini Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Silvana Saputri Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia
  • Prasenohadi Department Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine – Persahabatan Hospital, Jakarta, Indonesia

DOI:

https://doi.org/10.3855/jidc.17268

Keywords:

COVID-19, vaccination, booster, Moderna, healthcare providers

Abstract

Introduction: As an endeavor to control SARS-CoV-2 infection, the Moderna vaccine booster was given to healthcare workers to prevent reinfection and reduce the risk of complications from COVID-19. A heterologous booster vaccine is also thought to provide better protection against the current SARS-CoV-2 variants of concern. However, research that evaluates the effectiveness of the Moderna vaccine booster and the resulting SARS-CoV-2 antibody concentration is needed.

Objective: To evaluate the concentration of SARS-CoV-2 antibodies after the Moderna vaccine booster and the severity of SARS-CoV-2 infection before and after the Moderna vaccine booster.

Results: A total of 93 healthcare providers who received Moderna vaccine booster were included in the study. Examination of antibody concentration 3 months after the booster showed an average concentration of 10081.65 U/mL. There was an increase in antibody concentration before the booster and 3 months after, from a median of 1.7 U/mL to 9540 U/mL. Every subject showed a statistically significant increment of antibody concentration 3 months after the booster (p < 0.01). Thirty-seven (39.8%) subjects received two doses of the Sinovac vaccine and were confirmed to have COVID-19 with the Delta variant. After the booster, 26 (28%) subjects were infected with the Omicron Variant. Among the subjects who received two doses of the Sinovac vaccine and were confirmed with COVID-19, 36 (30.1%) had mild symptoms, and 1 (1.1%) was asymptomatic.

Conclusions: Heterologous Moderna vaccine booster effectively increases antibody response against SARS-CoV-2 variants and shows mild symptoms of COVID-19 infection.

Downloads

Published

2023-05-31

How to Cite

1.
Fachrucha F, Sutoyo DK, Nurwidya F, Andarini SL, Susanto AD, Isbaniah F, Handayani D, Yunus F, Soehardiman D, Zaini J, Saputri S, Prasenohadi (2023) Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers. J Infect Dev Ctries 17:617–622. doi: 10.3855/jidc.17268

Issue

Vol. 17 No. 05: May 2023

Section

Coronavirus Pandemic

License

Copyright (c) 2023 Fanny Fachrucha, Dianiati Kusumo Sutoyo, Fariz Nurwidya, Sita Laksmi Andarini, Agus Dwi Susanto, Fathiyah Isbaniah, Diah Handayani, Faisal Yunus, Dicky Soehardiman, Jamal Zaini, Silvana Saputri, Prasenohadi Prasenohadi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC